Bionor Immuno As
Records under this name other than the patents Bionor Immuno As holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 4 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,925,691 | Drill bit Lapsed on the fee record Ended Mar 27, 2026 · From the USPTO record | Lapsed on the fee record | Ended Mar 27, 2026 | From the USPTO record |
| US 9,493,514 | Dimeric scaffold proteins comprising HIV-1 GP120 and GP41 epitopes Lapsed on the fee record Ended Nov 15, 2024 · From the USPTO record | Lapsed on the fee record | Ended Nov 15, 2024 | From the USPTO record |
| US 10,449,245 | Method for reducing HIV-1 reservoir size using multivalent immunogen and reservoir purging agent Lapsed on the fee record Ended Oct 22, 2023 · From the USPTO record | Lapsed on the fee record | Ended Oct 22, 2023 | From the USPTO record |
| US 10,143,737 | Method for the vaccination against HIV Lapsed on the fee record Ended Dec 4, 2022 · From the USPTO record | Lapsed on the fee record | Ended Dec 4, 2022 | From the USPTO record |
| US 10,124,059 | Dimeric scaffold peptides comprising HIV-1 GP120 and GP41 epitopes Lapsed on the fee record Ended Nov 13, 2022 · From the USPTO record | Lapsed on the fee record | Ended Nov 13, 2022 | From the USPTO record |
| US 6,706,859 | HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV Term ended Term ended Nov 3, 2020 · From the USPTO record | Term ended | Term ended Nov 3, 2020 | From the USPTO record |
| US 7,311,915 | Method of producing an HIV-1 immune response Lapsed on the fee record Ended Dec 25, 2019 · From the USPTO record | Lapsed on the fee record | Ended Dec 25, 2019 | From the USPTO record |
| US 9,200,065 | Peptide constructs derived from the GP120 C5 domain and GP41 transmembrane domain Lapsed on the fee record Ended Dec 1, 2019 · From the USPTO record | Lapsed on the fee record | Ended Dec 1, 2019 | From the USPTO record |
| US 7,709,003 | Method of producing an HIV-1 immune response Lapsed on the fee record Ended May 4, 2018 · From the USPTO record | Lapsed on the fee record | Ended May 4, 2018 | From the USPTO record |
| US 7,709,004 | Method of producing an HIV-1 immune response Lapsed on the fee record Ended May 4, 2018 · From the USPTO record | Lapsed on the fee record | Ended May 4, 2018 | From the USPTO record |